Taletrectinib Takes Aim: A New Chapter in ROS1-Positive NSCLC
Season 2, Episode 59, Jul 30, 08:33 PM
Share
Subscribe
Kevin Chen, PharmD, MS, BCOP, CPP, and Amanda Cass, PharmD, BCPS, BCOP, share key insights about ROS1, non-small cell lung cancer, and the new approved drug taletrectinib.